secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024177
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio reports Q3 2022 net loss of $7.4M; updates on INB-100 and INB-400 programs
--------------------------------------------------------------------------------

- Net loss of $7.4M ($0.34/share) for Q3 2022 vs $3.4M ($0.25) in Q3 2021; R&D expenses rose to $4.3M.
- Cash of $27.6M as of Sep 30, 2022, down from $37.0M at Dec 31, 2021; raised $9.8M net from equity offering.
- INB-100 Phase 1: all three high-risk AML patients show durable morphologic CR >1 year; two >2 years; no DLTs; ASH data planned.
- Filed IND for INB-400; partnered with Univ of Louisville for GMP manufacturing for Phase 2 trial.
- Appointed Kenneth LaMontagne as SVP Business Development; added Dr. Michael Bishop to Scientific Advisory Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017022024177/0000950170-22-024177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017022024177/inab-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer